fatty-liver

Documents about fatty-liver

• Physical activity, fatty acids, and MASLD risk: Behavioural and metabolic factors jointly shaping liver health in populations#343651bioRxiv / medRxiv
• De Novo Lipogenesis in Severity of NAFLD#366543ClinicalTrials.gov
• Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content#391017ClinicalTrials.gov
• Hepatic Urea Nitrogen Handling in Patients With NASH#857971ClinicalTrials.gov
• The Evaluation of Orange Peel Fermentation on Body Fat Lowering Efficacy in Adults#873304ClinicalTrials.gov
• Mechanisms of Macrophage Polarization in HIRI in Patients With NAFLD#979070ClinicalTrials.gov
• The Impact of Almond Nut Consumption on Markers of CVD & Metabolic Health#847298ClinicalTrials.gov
• Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Nonalcoholic Fatty Liver Disease#424316ClinicalTrials.gov
• Effect of Indo-Mediterranean Diet on Hepatic Steatosis and Fibrosis in NAFLD Children#886395ClinicalTrials.gov
• Association Between Non-alcoholic Fatty Liver Disease (NAFLD) and Coronary Artery Calcification#981450ClinicalTrials.gov
• Implementation of Combinational Deep Learning Algorithm for Non-alcoholic Fatty Liver Classification in Ultrasound Images#163483WIPO
• Study on MAFLD-related Cirrhosis Prevention and Treatment Strategies#332726ClinicalTrials.gov
• RCT of Caloric Restriction vs. Alternate-Day Fasting in Non-Alcoholic Fatty Liver Disease#391043ClinicalTrials.gov
• Early Tracking of Childhood Health Determinants (ETCHED) Study#398281ClinicalTrials.gov
• A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes.#407862ClinicalTrials.gov
• Eosinophilic Esophagitis and Risk of Non-Alcoholic Fatty Liver Disease and Cirrhosis: A Multi-Center Retrospective Study.#409518NCBI PubMed Central
• Predicting Obesity Consequences Using Body Measure and Urine Metabolomics#870505ClinicalTrials.gov
• Efficacy and Safety of a Probiotic Composition as Adjunct in MAFL Management#874455ClinicalTrials.gov
• Metabolic Liver Disease in Newly Diagnosed People Living With HIV (MASHIV-TR)#802659ClinicalTrials.gov
• Characterization of the Microbiome in Peritoneum, Jejunum, Rectum and Stool#195480ClinicalTrials.gov
• The Effects of a Novel Lifestyle Intervention Program on Insulin Sensitivity in Type 2 Diabetes#332704ClinicalTrials.gov
• Determination of the Effect of Extreme Dietary Carbohydrate Restriction on Hepatic Glucose Production#405288ClinicalTrials.gov
• Effect of Intermittent Calorie Restriction on MASLD Patients With Abnormal Glucose Metabolism#471561ClinicalTrials.gov
• Nonalcoholic Fatty Liver Disease as a Risk Marker for Incident Type 2 Diabetes Mellitus: A Systematic Review.#621024NCBI PubMed Central
• The Effect of Curcumin on the Development of Prednisolone-induced Hepatic Insulin Resistance#683031ClinicalTrials.gov
• Metabolic dysfunction-associated fatty liver disease exacerbates hematoma expansion in intracerebral hemorrhage: an explainable machine learning approach.#685601NCBI PubMed Central
• Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH#858639ClinicalTrials.gov
• Vitamin E Dosing Study#903778ClinicalTrials.gov
• The Study of Lithogenesis Processes in Patients With Non-alcoholic Fatty Liver Disease (NAFLD)#908290ClinicalTrials.gov
• Screening for Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD) at Al-Rajhy Hospital Nutrition Clinic. Assiut, Egypt#969045ClinicalTrials.gov
• Role Of Serum Adiponectin In The Ealy Detection Of Renal Impairment In Patients With Non Alcoholic Fatty Liver Disease#1033390ClinicalTrials.gov
• Retrospective analysis of predictors for significant hepatic inflammation in metabolic-associated fatty liver disease with chronic hepatitis B.#170643NCBI PubMed Central
• Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)#208417ClinicalTrials.gov
• Hepatic and Cardiac Metabolic Flexibility in Subjects With T2DM With and Without NAFLD#283194ClinicalTrials.gov
• Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents#325249ClinicalTrials.gov
• Integrated Multi-omics Data for Personalized Treatment of Obesity-associated Fatty Liver Disease#460016ClinicalTrials.gov
• Omega-3 Fatty Acids in Bariatric Gastric Bypass Surgery: Effect on Liver Volume, Immune Response and Erythrocyte Function#805871ClinicalTrials.gov
• Effect of Molecular Hydrogen in Patients With NAFLD#871709ClinicalTrials.gov
• Transcriptomic analysis identifies FABP5 as a candidate regulator of lipid accumulation in metabolic dysfunction-associated fatty liver disease.#923531NCBI PubMed Central
• To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects#980297ClinicalTrials.gov
• Efficacy of Orlistat on Cardiometabolic Indices in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A GRADE-Assessed Systematic Review and Meta-Analysis of RCTs#5281Europe PMC
• Hepatic Histology and Metabolism Following Total Pancreatectomy and Pancreaticoduodenectomy#885067ClinicalTrials.gov
• Rosiglitazone Versus Rosiglitazone and Metformin Versus Rosiglitazone and Avandia in the Treatment of Nonalcoholic Steatohepatitis (NASH)#121313ClinicalTrials.gov
• Mechanistic Evaluation Of Menstrual Blood-Derived Endometrial Stem Cells In Mutine Models Of Alsoholic And Non-Alcoholic Fatty Liver Disease#216363USM Repository
• Iron Depletion Therapy for Type 2 DM and NAFLD#303652ClinicalTrials.gov
• The Clock Thickens: Morning or Evening Training for the Treatment of NAFLD?#849762ClinicalTrials.gov
• Neuroprotective and Cardioprotective Effects Of Palm Vitamin E Tocotrienols#873832ClinicalTrials.gov
• A Preliminary Study to Evaluate Cysteamine Therapy in Human Subjects With Non-Alcoholic Steatohepatitis (NASH)#903920ClinicalTrials.gov
• The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis#918711ClinicalTrials.gov
• Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH#1032275ClinicalTrials.gov